PDE4 inhibitors serve as therapeutic targets for pulmonary fibrosis
10.12092/j.issn.1009-2501.2023.03.015
- Author:
Nanyu LIU
1
;
Hongmei YUE
1
;
Peipei SONG
1
;
Jifang WEI
1
;
Yaqian WEI
1
;
Yingying XIE
1
;
Jiaqi WANG
1
;
Hongmei YUE
2
Author Information
1. The First Clinical Medical College, Lanzhou University
2. Department of Respiratory Medicine, The First Hospital of Lanzhou University
- Publication Type:Journal Article
- Keywords:
cAMP;
PDE4;
PDE4 inhibitors;
pulmonary fibrosis
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2023;28(3):355-360
- CountryChina
- Language:Chinese
-
Abstract:
Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal chronic interstitial lung disease characterized by a progressive decline in lung function, and current treatment options are limited. cAMP is one of the most important second messengers and plays a key role in relaxing airway smooth muscle cells and reducing inflammation. Phosphodiesterase (PDE) is a superfamily of enzymes, and PDE4 enzymes dominate 11 PDE superfamily enzymes, available in four isoforms-PDE4A, PDE4B, PDE4C and PDE4D, which selectively decompose cAMP, while PDE4 inhibitors increase cAMP levels by preventing cAMP from breaking down, thereby exerting anti-inflammatory, anti-remodeling effects and providing an attractive drug target for the treatment of IPF. This review summarizes knowledge about the association of pulmonary fibrosis with PKE4, as well as emerging preclinical studies and clinical trials regarding PDE4 inhibitors.
